{"id":522165,"date":"2021-08-03T09:03:07","date_gmt":"2021-08-03T13:03:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/"},"modified":"2021-08-03T09:03:07","modified_gmt":"2021-08-03T13:03:07","slug":"first-case-performed-using-natus-xacttrode-subdural-electrodes","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/","title":{"rendered":"First Case Performed Using Natus XactTrode\u2122 Subdural Electrodes"},"content":{"rendered":"

\nLaunch to US Market of XactTrodes for Epilepsy Surgical Monitoring
\n<\/h2>\n
\n

PLEASANTON, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) — Natus Medical Incorporated <\/strong>(NASDAQ:NTUS) (the \u201cCompany\u201d or \u201cNatus\u201d), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all\u00a0ages, is pleased to announce the completion of the first successfully performed clinical case using Natus\u2019 newly launched XactTrode\u2122 family of platinum subdural electrodes. The Natus XactTrodes are intended for temporary (< 30 days) use with recording, monitoring and stimulation of electrical signals on the surface of the brain.<\/p>\n

\u201cWe are pleased that the surgical team found the XactTrodes to be an excellent solution for both anatomic fit and signal performance,\u201d says Jonathan Kennedy, Natus CEO. \u201cNatus is thrilled to now offer XactTrodes to our customers. We designed them to work seamlessly with our market leading Quantum system, which will provide care teams greater efficiency and performance.\u201d<\/p>\n

For more information about XactTrodes, please visit https:\/\/neuro.natus.com\/products-services\/subdural-electrodes<\/a>.<\/p>\n

\n About Natus Medical Incorporated<\/strong>\n <\/p>\n

Natus Medical Incorporated\u00a0improves patient outcomes using the most comprehensive product solutions, depth of training and continuing customer care\u00a0when diagnosing and treating central nervous and sensory system disorders for patients of all ages.<\/p>\n

Additional information about Natus Medical Incorporated can be found at https:\/\/natus.com<\/a>.<\/p>\n

Contacts:
Natus Medical Incorporated
Drew Davies
Executive Vice President and Chief Financial Officer
(925) 223-6700
InvestorRelations@Natus.com<\/a>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Launch to US Market of XactTrodes for Epilepsy Surgical Monitoring PLEASANTON, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) — Natus Medical Incorporated (NASDAQ:NTUS) (the \u201cCompany\u201d or \u201cNatus\u201d), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all\u00a0ages, is pleased to announce the completion of the first successfully performed clinical case using Natus\u2019 newly launched XactTrode\u2122 family of platinum subdural electrodes. The Natus XactTrodes are intended for temporary (< 30 days) use with recording, monitoring and stimulation of electrical signals on the surface of the brain. \u201cWe are pleased that the surgical team found the XactTrodes to be an excellent solution for both anatomic fit and signal performance,\u201d … <\/p>\n

Continue reading “First Case Performed Using Natus XactTrode\u2122 Subdural Electrodes”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-522165","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFirst Case Performed Using Natus XactTrode\u2122 Subdural Electrodes - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First Case Performed Using Natus XactTrode\u2122 Subdural Electrodes - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Launch to US Market of XactTrodes for Epilepsy Surgical Monitoring PLEASANTON, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) — Natus Medical Incorporated (NASDAQ:NTUS) (the \u201cCompany\u201d or \u201cNatus\u201d), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all\u00a0ages, is pleased to announce the completion of the first successfully performed clinical case using Natus\u2019 newly launched XactTrode\u2122 family of platinum subdural electrodes. The Natus XactTrodes are intended for temporary (< 30 days) use with recording, monitoring and stimulation of electrical signals on the surface of the brain. \u201cWe are pleased that the surgical team found the XactTrodes to be an excellent solution for both anatomic fit and signal performance,\u201d … Continue reading "First Case Performed Using Natus XactTrode\u2122 Subdural Electrodes"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-03T13:03:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMDkzNCM0MzM2MjgwIzIwMjg2Njc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-case-performed-using-natus-xacttrode-subdural-electrodes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-case-performed-using-natus-xacttrode-subdural-electrodes\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"First Case Performed Using Natus XactTrode\u2122 Subdural Electrodes\",\"datePublished\":\"2021-08-03T13:03:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-case-performed-using-natus-xacttrode-subdural-electrodes\\\/\"},\"wordCount\":242,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-case-performed-using-natus-xacttrode-subdural-electrodes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMDkzNCM0MzM2MjgwIzIwMjg2Njc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-case-performed-using-natus-xacttrode-subdural-electrodes\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-case-performed-using-natus-xacttrode-subdural-electrodes\\\/\",\"name\":\"First Case Performed Using Natus XactTrode\u2122 Subdural Electrodes - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-case-performed-using-natus-xacttrode-subdural-electrodes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-case-performed-using-natus-xacttrode-subdural-electrodes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMDkzNCM0MzM2MjgwIzIwMjg2Njc=\",\"datePublished\":\"2021-08-03T13:03:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-case-performed-using-natus-xacttrode-subdural-electrodes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-case-performed-using-natus-xacttrode-subdural-electrodes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-case-performed-using-natus-xacttrode-subdural-electrodes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMDkzNCM0MzM2MjgwIzIwMjg2Njc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMDkzNCM0MzM2MjgwIzIwMjg2Njc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-case-performed-using-natus-xacttrode-subdural-electrodes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First Case Performed Using Natus XactTrode\u2122 Subdural Electrodes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First Case Performed Using Natus XactTrode\u2122 Subdural Electrodes - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/","og_locale":"en_US","og_type":"article","og_title":"First Case Performed Using Natus XactTrode\u2122 Subdural Electrodes - Market Newsdesk","og_description":"Launch to US Market of XactTrodes for Epilepsy Surgical Monitoring PLEASANTON, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) — Natus Medical Incorporated (NASDAQ:NTUS) (the \u201cCompany\u201d or \u201cNatus\u201d), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all\u00a0ages, is pleased to announce the completion of the first successfully performed clinical case using Natus\u2019 newly launched XactTrode\u2122 family of platinum subdural electrodes. The Natus XactTrodes are intended for temporary (< 30 days) use with recording, monitoring and stimulation of electrical signals on the surface of the brain. \u201cWe are pleased that the surgical team found the XactTrodes to be an excellent solution for both anatomic fit and signal performance,\u201d … Continue reading \"First Case Performed Using Natus XactTrode\u2122 Subdural Electrodes\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-03T13:03:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMDkzNCM0MzM2MjgwIzIwMjg2Njc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"First Case Performed Using Natus XactTrode\u2122 Subdural Electrodes","datePublished":"2021-08-03T13:03:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/"},"wordCount":242,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMDkzNCM0MzM2MjgwIzIwMjg2Njc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/","name":"First Case Performed Using Natus XactTrode\u2122 Subdural Electrodes - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMDkzNCM0MzM2MjgwIzIwMjg2Njc=","datePublished":"2021-08-03T13:03:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMDkzNCM0MzM2MjgwIzIwMjg2Njc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMDkzNCM0MzM2MjgwIzIwMjg2Njc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-case-performed-using-natus-xacttrode-subdural-electrodes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"First Case Performed Using Natus XactTrode\u2122 Subdural Electrodes"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/522165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=522165"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/522165\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=522165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=522165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=522165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}